AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16331394 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of early markers of neurodegenerative disorders in idiopathic RBD
Number of subjects: 0
Study 14629242 — intervention group
Group type: EXPERIMENTAL
Intervention: Almotriptan 12.5 mg
Number of subjects: 0
Study 10591431 — intervention group
Group type: EXPERIMENTAL
Intervention: Gordon Diagnostic System (GDS)
Number of subjects: 159
Study 10591431 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 159
Study 8913316 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte-macrophage colony-stimulating factor (GM-CSF) administration post-ABMT
Number of subjects: 34
Study 8913316 — intervention group
Group type: COMPARATOR
Intervention: Control group (no GM-CSF administration)
Number of subjects: 34
Study 1862207 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine (DMI) 200 mg daily
Number of subjects: 30
Study 1862207 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 1862207 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine (DMI)
Number of subjects: 30
Study 6849284 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet with 94 g protein
Number of subjects: 10
Study 6849284 — intervention group
Group type: COMPARATOR
Intervention: Diet with 65 g protein
Number of subjects: 10
Study 30686560 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic GOLD‐HAS hetero‐questionnaire
Number of subjects: 176
Study 30686560 — intervention group
Group type: EXPERIMENTAL
Intervention: Coordination of the patient's path to facilitate access to spirometry
Number of subjects: 176
Study 30686560 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of the two strategies (questionnaire and coordination)
Number of subjects: 176
Study 30686560 — intervention group
Group type: COMPARATOR
Intervention: Control arm (no intervention)
Number of subjects: 176
Study 30274848 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional consultation with additional video-assisted information (interventional group)
Number of subjects: 113
Study 30274848 — intervention group
Group type: COMPARATOR
Intervention: Conventional face-to-face consultation (conventional group)
Number of subjects: 113
Study 26304064 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative description of imprecision in risk
Number of subjects: 2663
Study 26304064 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative description of imprecision in risk
Number of subjects: 2663
Study 26304064 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative and quantitative methods
Number of subjects: 2663
Study 24316553 — intervention group
Group type: EXPERIMENTAL
Intervention: GOLFIG regimen (gemcitabine 1000 mg/m² on day 1; oxaliplatin 85 mg/m² on day 2; levofolinate 100 mg/m² on days 1-2; 5-fluorouracil 400 mg/m² bolus followed by 24 h infusion at 800 mg/m² on days 1-2; GM-CSF 100 μg subcutaneously days 3-7; aldesleukin 0.5 MIU bi-daily days 8-14 and 17-30)
Number of subjects: 0
Study 24316553 — intervention group
Group type: COMPARATOR
Intervention: FOLFOX chemotherapy
Number of subjects: 0
Study 22208418 — intervention group
Group type: EXPERIMENTAL
Intervention: Lottery incentive condition (64% completion rate)
Number of subjects: 1299
Study 22208418 — intervention group
Group type: COMPARATOR
Intervention: Grocery gift certificate condition (44% completion rate)
Number of subjects: 1299
Study 22208418 — intervention group
Group type: COMPARATOR
Intervention: Comparison condition (40% completion rate)
Number of subjects: 1299
Study 20113691 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling and root planing (active treatment)
Number of subjects: 757
Study 20113691 — intervention group
Group type: COMPARATOR
Intervention: Tooth polishing (control)
Number of subjects: 757
Study 17634538 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma TIMP-1
Number of subjects: 90
Study 15604046 — intervention group
Group type: EXPERIMENTAL
Intervention: New 3-item, 5-stage measure of smoking initiation and progression
Number of subjects: 2504
Study 12479631 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone/estrogen replacement therapy (HRT/ERT)
Number of subjects: 49
Study 10069881 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human IL-5 by nebulization
Number of subjects: 14
Study 10069881 — intervention group
Group type: COMPARATOR
Intervention: Vehicle challenge (Control)
Number of subjects: 14
Study 7496238 — intervention group
Group type: EXPERIMENTAL
Intervention: Disclosure of depression scores to general practitioners for subjects whose depression was undetected (45% of cases, 52 out of 116).
Number of subjects: 179
Study 7496238 — intervention group
Group type: COMPARATOR
Intervention: Detected depression cases by general practitioners.
Number of subjects: 179
Study 7496238 — intervention group
Group type: COMPARATOR
Intervention: Intention to treat analysis.
Number of subjects: 179
Study 7496238 — intervention group
Group type: COMPARATOR
Intervention: Disclosure of undetected depression.
Number of subjects: 179
Study 2178384 — intervention group
Group type: EXPERIMENTAL
Intervention: milrinone (10 mg 4 times a day)
Number of subjects: 16
Study 2178384 — intervention group
Group type: EXPERIMENTAL
Intervention: captopril (50 mg 3 times a day)
Number of subjects: 16
Study 2178384 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 16
Study 224478 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus BCG
Number of subjects: 100
Study 224478 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 100
Study 31099213 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture once every day
Number of subjects: 180
Study 31099213 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture once every 2 days
Number of subjects: 180
Study 31099213 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture once every 3 days
Number of subjects: 180
Study 28094662 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT)
Number of subjects: 129
Study 28094662 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 129
Study 26316598 — intervention group
Group type: EXPERIMENTAL
Intervention: Laboratory and clinical monitoring (LCM)
Number of subjects: 2946
Study 26316598 — intervention group
Group type: COMPARATOR
Intervention: Clinical monitoring (CDM)
Number of subjects: 2946
Study 26316598 — intervention group
Group type: EXPERIMENTAL
Intervention: Single CD4 test at 48 weeks
Number of subjects: 2946
Study 26316598 — intervention group
Group type: EXPERIMENTAL
Intervention: No CD4 testing
Number of subjects: 2946
Study 26316598 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-weekly CD4 testing
Number of subjects: 2946
Study 23159435 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (40 mg twice daily)
Number of subjects: 43
Study 23159435 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 21773891 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrocautery (group E)
Number of subjects: 100
Study 21773891 — intervention group
Group type: COMPARATOR
Intervention: Scalpel (group S)
Number of subjects: 100
Study 19714289 — intervention group
Group type: EXPERIMENTAL
Intervention: Transnasal FICE system
Number of subjects: 72
Study 16394035 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV16 L1 VLP vaccine
Number of subjects: 2391
Study 16394035 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2391
Study 15488358 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity counseling
Number of subjects: 70
Study 15488358 — intervention group
Group type: COMPARATOR
Intervention: Control (no physical activity counseling)
Number of subjects: 70
Study 12051309 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (250 mg)
Number of subjects: 20
Study 12051309 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 9744512 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant treatments (specific treatments not detailed)
Number of subjects: 2687
Study 7640648 — intervention group
Group type: EXPERIMENTAL
Intervention: Antagonist passive stretch (APS), 6‐sec maximal voluntary isometric contraction (MVIC) of the antagonist, and subsequent APS
Number of subjects: 60
Study 7640648 — intervention group
Group type: EXPERIMENTAL
Intervention: Antagonist passive stretch (APS), 6‐sec MVIC of the antagonist, submaximal concentric contraction of the agonist, and APS
Number of subjects: 60
Study 7640648 — intervention group
Group type: EXPERIMENTAL
Intervention: Antagonist passive stretch (APS), submaximal concentric contraction of the agonist, and APS (without MVIC)
Number of subjects: 60
Study 2758730 — intervention group
Group type: EXPERIMENTAL
Intervention: Pinacidil 12.5 mg with Hydrochlorothiazide 12.5 mg
Number of subjects: 384
Study 2758730 — intervention group
Group type: EXPERIMENTAL
Intervention: Pinacidil 37.5 mg monotherapy
Number of subjects: 384
Study 2758730 — intervention group
Group type: COMPARATOR
Intervention: Pinacidil (0, 12.5, 25, and 37.5 mg, b.i.d.)
Number of subjects: 384
Study 2758730 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (0, 12.5, and 25 mg, b.i.d.)
Number of subjects: 384
Study 105443 — intervention group
Group type: EXPERIMENTAL
Intervention: Orgotein injected after each daily irradiation session
Number of subjects: 0
Study 105443 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31652241 — intervention group
Group type: EXPERIMENTAL
Intervention: Exergaming (EG) program
Number of subjects: 29
Study 31652241 — intervention group
Group type: COMPARATOR
Intervention: Traditional physical exercise (TPE) program
Number of subjects: 29
Study 30095736 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard countermovement push-up (CMP)
Number of subjects: 37
Study 30095736 — intervention group
Group type: EXPERIMENTAL
Intervention: Kneeling countermovement push-up (CMP)
Number of subjects: 37
Study 30095736 — intervention group
Group type: EXPERIMENTAL
Intervention: Drop-fall push-up (CMP)
Number of subjects: 37
Study 30095736 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard squat push-up (SP)
Number of subjects: 37
Study 30095736 — intervention group
Group type: EXPERIMENTAL
Intervention: Kneeling squat push-up (SP)
Number of subjects: 37
Study 28153102 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab
Number of subjects: 3340
Study 28153102 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 3340
Study 26077375 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-soya legume-based TLC diet
Number of subjects: 31
Study 26077375 — intervention group
Group type: COMPARATOR
Intervention: Isoenergetic legume-free TLC diet
Number of subjects: 31
Study 23480233 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus predose concentrations at five time points (day 3, 10, 14, month 1, and month 6 after transplantation)
Number of subjects: 1304
Study 23480233 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed graft function (DGF)
Number of subjects: 1304
Study 23480233 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction therapy
Number of subjects: 1304
Study 21074910 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative immunomodulating enteral diet (IMEN)
Number of subjects: 305
Study 21074910 — intervention group
Group type: COMPARATOR
Intervention: Standard oligopeptide diet (SEN)
Number of subjects: 305
Study 19584344 — intervention group
Group type: EXPERIMENTAL
Intervention: Tubular diskectomy
Number of subjects: 328
Study 19584344 — intervention group
Group type: COMPARATOR
Intervention: Conventional microdiskectomy
Number of subjects: 328
Study 17074301 — intervention group
Group type: EXPERIMENTAL
Intervention: Eight-week cognitive-behavioral workshop (2 hours per week, in groups of 10)
Number of subjects: 240
Study 17074301 — intervention group
Group type: COMPARATOR
Intervention: Assessment-only control group
Number of subjects: 240
Study 15447818 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine granules (0.5 g.kg(‐1).d(‐1) orally for 7 days)
Number of subjects: 120
Study 15447818 — intervention group
Group type: COMPARATOR
Intervention: Placebo (glycine, same dosage for 7 days)
Number of subjects: 120
Study 15447818 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine granules
Number of subjects: 120
Study 15447818 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Gln and C)
Number of subjects: 120
Study 11257247 — intervention group
Group type: EXPERIMENTAL
Intervention: IUD‐Cu 380A
Number of subjects: 95
Study 11257247 — intervention group
Group type: EXPERIMENTAL
Intervention: IUD‐Cu 200B
Number of subjects: 95
Study 11257247 — intervention group
Group type: COMPARATOR
Intervention: Control (no IUD)
Number of subjects: 95
Study 9621674 — intervention group
Group type: EXPERIMENTAL
Intervention: Warmed solution using HOT LINE
Number of subjects: 35
Study 9621674 — intervention group
Group type: COMPARATOR
Intervention: Unwarmed solution
Number of subjects: 35
Study 9621674 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow infusion rate
Number of subjects: 35
Study 30220702 — intervention group
Group type: EXPERIMENTAL
Intervention: Phacoemulsification cataract surgery
Number of subjects: 49
Study 30220702 — intervention group
Group type: COMPARATOR
Intervention: Control group (no phacoemulsification cataract surgery)
Number of subjects: 49
Study 28459932 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding promotion intervention
Number of subjects: 13557
Study 28459932 — intervention group
Group type: COMPARATOR
Intervention: Control group (no breastfeeding promotion)
Number of subjects: 13557
Study 24062278 — intervention group
Group type: EXPERIMENTAL
Intervention: Canine-assisted intervention (CAI)
Number of subjects: 24
Study 24062278 — intervention group
Group type: COMPARATOR
Intervention: Cognitive-behavioral therapy without CAI
Number of subjects: 24
Study 24001483 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate open repair
Number of subjects: 2226
Study 24001483 — intervention group
Group type: COMPARATOR
Intervention: Surveillance
Number of subjects: 2226
Study 24001483 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate open repair (Men)
Number of subjects: 2226
Study 24001483 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate open repair (Women)
Number of subjects: 2226
Study 19492709 — intervention group
Group type: EXPERIMENTAL
Intervention: Sealing with polyurethane-dimethacrylate foil using a bonding agent
Number of subjects: 50
Study 19492709 — intervention group
Group type: COMPARATOR
Intervention: Oral home care with dental floss and fluoridated toothpaste (Control)
Number of subjects: 50
Study 17227498 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 20 mg on-demand before sexual activity
Number of subjects: 4262
Study 17227498 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 20 mg three times per week for 5-6 weeks
Number of subjects: 4262
Study 17227498 — intervention group
Group type: COMPARATOR
Intervention: Tadalafil 20 mg on-demand
Number of subjects: 4262
Study 17227498 — intervention group
Group type: COMPARATOR
Intervention: Tadalafil 20 mg three times per week
Number of subjects: 4262
Study 15593037 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrapure dialysate
Number of subjects: 34
Study 15593037 — intervention group
Group type: COMPARATOR
Intervention: Conventional dialysate
Number of subjects: 34
Study 11767810 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Protocol (MP)
Number of subjects: 80
Study 11767810 — intervention group
Group type: COMPARATOR
Intervention: Traditional Protocol (TP)
Number of subjects: 80
Study 11767810 — intervention group
Group type: EXPERIMENTAL
Intervention: Pooled sample (excluding dropouts)
Number of subjects: 80
Study 9648957 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole, 40 mg b.i.d. for 3 months
Number of subjects: 36
Study 9648957 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 7861594 — intervention group
Group type: EXPERIMENTAL
Intervention: Celiac plexus block (CPB) with 99.5% ethanol 15-20 ml
Number of subjects: 24
Study 7861594 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic epidural block (TEB) with 2% lidocaine
Number of subjects: 24
Study 7861594 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 24
Study 2909549 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium fluoride (25 mg twice daily) with 25-hydroxyvitamin D (50 micrograms twice weekly) and calcium supplements (total calcium intake 1500 mg/day)
Number of subjects: 24
Study 897571 — intervention group
Group type: EXPERIMENTAL
Intervention: Coenzyme-B12
Number of subjects: 2
Study 897571 — intervention group
Group type: COMPARATOR
Intervention: Cyanocobalamin
Number of subjects: 2
Study 31439531 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical antiseptic ointment
Number of subjects: 137
Study 31439531 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical decongestant ointment
Number of subjects: 137
Study 31439531 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemical cauterization
Number of subjects: 137
Study 31439531 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical antiseptic ointment + chemical cauterization
Number of subjects: 137
Study 31439531 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical decongestant ointment + chemical cauterization
Number of subjects: 137
Study 31484191 — intervention group
Group type: EXPERIMENTAL
Intervention: Cynara scolymus (500 mg twice daily)
Number of subjects: 40
Study 31484191 — intervention group
Group type: COMPARATOR
Intervention: Placebo (starch powder)
Number of subjects: 40
Study 31639167 — intervention group
Group type: EXPERIMENTAL
Intervention: King Vision™ aBlade™ channeled video laryngoscope
Number of subjects: 105
Study 31639167 — intervention group
Group type: EXPERIMENTAL
Intervention: McGRATH™ MAC video laryngoscope
Number of subjects: 105
Study 31639167 — intervention group
Group type: COMPARATOR
Intervention: King Vision™ aBlade™ non‐channeled video laryngoscope
Number of subjects: 105
Study 28418082 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplementation with resistant starch (RS) and polydextrose (PD)
Number of subjects: 0
Study 28418082 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26266387 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 40
Study 26266387 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 40
Study 23325750 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy (CPT)
Number of subjects: 86
Study 23325750 — intervention group
Group type: COMPARATOR
Intervention: Present-Centered Therapy (PCT)
Number of subjects: 86
Study 21809964 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 0
Study 21809964 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18926865 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise 2h after a meal
Number of subjects: 12
Study 18926865 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise 1h before a meal
Number of subjects: 12
Study 18926865 — intervention group
Group type: COMPARATOR
Intervention: Meal consumption
Number of subjects: 12
Study 17713973 — intervention group
Group type: EXPERIMENTAL
Intervention: CP-481,715 (up to 3000 mg)
Number of subjects: 78
Study 17713973 — intervention group
Group type: EXPERIMENTAL
Intervention: CP-481,715 (300 mg) with ciclosporin
Number of subjects: 78
Study 17713973 — intervention group
Group type: EXPERIMENTAL
Intervention: CP-481,715 (300 mg) without ciclosporin
Number of subjects: 78
Study 17713973 — intervention group
Group type: EXPERIMENTAL
Intervention: CP-481,715 (escalating doses)
Number of subjects: 78
Study 17713973 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study 15389187 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab 3 mg/kg
Number of subjects: 249
Study 15389187 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab 5 mg/kg
Number of subjects: 249
Study 15389187 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 249
Study 15389187 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 249
Study 11162416 — intervention group
Group type: EXPERIMENTAL
Intervention: budesonide/formoterol 160/4.5 microg (1 inhalation)
Number of subjects: 30
Study 11162416 — intervention group
Group type: EXPERIMENTAL
Intervention: budesonide/formoterol 160/4.5 microg (2 inhalations)
Number of subjects: 30
Study 11162416 — intervention group
Group type: COMPARATOR
Intervention: salmeterol/fluticasone 50/250 microg
Number of subjects: 30
Study 11162416 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 30
Study 9783305 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom Score (SS) assessment during treatment for acute lymphoblastic leukemia (ALL)
Number of subjects: 30
Study 9783305 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom Score (SS) assessment during treatment for solid tumors receiving megatherapy with autologous bone marrow rescue
Number of subjects: 30
Study 9783305 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom Score (SS) assessment during treatment for miscellaneous tumors
Number of subjects: 30
Study 9783305 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom Score (SS) correlation with protein breakdown in paired WBPT studies
Number of subjects: 30
Study 9783305 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom Score (SS) correlation with fever and neutrophil count
Number of subjects: 30
Study 7872756 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosfomycin trometamol (3 g single dose)
Number of subjects: 112
Study 7872756 — intervention group
Group type: COMPARATOR
Intervention: Cephalexin (0.5 g four times daily for 5 days)
Number of subjects: 112
Study 2969740 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg doxazosin
Number of subjects: 114
Study 2969740 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg doxazosin
Number of subjects: 114
Study 2969740 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg doxazosin
Number of subjects: 114
Study 2969740 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin (combined regimens)
Number of subjects: 114
Study 2969740 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 114
Study 2969740 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 114
Study 2969740 — intervention group
Group type: COMPARATOR
Intervention: Doxazosin and Placebo
Number of subjects: 114
Study 31899950 — intervention group
Group type: EXPERIMENTAL
Intervention: Maize-based diet
Number of subjects: 360